Keywords: Novartis, Rasitrio, Hypertension, Bristol-Myers Squibb, Reyataz, HIV in pregnant women, European Commission, Label

European Commission OKs Novartis’ Rasitrio and new label for Bristol-Myers’ Reyataz

Article | 28 November 2011

Print This

Following a positive advisory recommendation in September, the European Commission has now approved Swiss drug major Novartis’ (NOVN: VX) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in